Merck & Co Inc MRK

Stock XNYS Rating as of Jul 10, 2026

$123.54 −1.53 (1.22%)

View Full Chart

As of Jul 10, 2026, 8:01:55 PM Delayed Price Closed

Company Report

View Archive

Merck's Portfolio and Solid Late-Stage Pipeline Defend Against Upcoming Keytruda Headwinds

Karen Andersen Sep 2, 2025

Merck's combination of a wide lineup of high-margin drugs and a pipeline of new drugs should ensure strong returns on invested capital over the long term. While we expect the firm could see sales declines in the late 2020s as patents in core oncology drug Keytruda expire in the US, it is likely that pipeline launches will limit these declines to a roughly two-year period during 2029-30. On the pipeline front, after several years of only moderate research and development productivity, Merck's drug development strategy is yielding important new drugs.

Read Full Report

Price vs Fair Value

View History

MRK is trading at a LOCK|m%lpf^@ premium.

Price

$123.54

Jul 10, 2026

Fair Value

s<%

Feb 4, 2025

Uncertainty

LOCK|svxPW

1-Star Price: LOCK|X.hM<
5-Star Price: LOCK|.@
Economic Moat: LOCK|ZF
Capital Allocation: LOCK|tR@QY??

Bulls Say, Bears Say

Bulls

Keytruda's leadership position in the immuno-oncology landscape, buoyed by a first-mover advantage in first-line non-small cell lung cancer, could become even further entrenched as Merck and other firms test new combinations with the drug.

Bears

The US patent loss on Keytruda in 2028 is concerning, given the high sales contribution of the drug (46% of 2024 sales).

News

View All

Articles & Videos

Trading Information

Previous Close Price: $125.07
Day Range: $122.90–125.56
52-Week Range: $76.66–130.29
Bid/Ask: $123.12 / $124.05
Shares Outstanding: 2.47B
Market Cap: $305.12B
Volume/Avg: 8M / 10M

Key Statistics

Price/Earnings (Normalized): 23.56
Price/Sales: 4.88
Dividend Yield (Trailing): 2.72%
Dividend Yield (Forward): 2.75%
Total Yield: 4.29%

Company Profile

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).

Sector: Healthcare
Industry: Drug Manufacturers - General
Stock Style Box: Large Value
Total Number of Employees: 75,000
Website: https://www.merck.com

Competitors

Valuation

Metric	MRK	LLY	BMY
Price/Earnings (Normalized)	23.56	42.00	9.81
Price/Book Value	6.94	35.39	5.90
Price/Sales	4.88	15.36	2.44
Price/Cash Flow	14.11	41.29	8.03

Price/Earnings

MRK

LLY

BMY

Financial Strength

Metric	MRK	LLY	BMY
Quick Ratio	0.66	0.72	1.18
Current Ratio	1.30	1.50	1.42
Interest Coverage	8.46	—	6.31

Quick Ratio

MRK

LLY

BMY

Profitability

Metric	MRK	LLY	BMY
Return on Assets (Normalized)	10.95%	24.73%	13.15%
Return on Equity (Normalized)	27.75%	114.33%	65.90%
Return on Invested Capital (Normalized)	16.06%	40.96%	19.89%

Return on Assets

MRK

LLY

BMY

Drug Manufacturers - General Industry Comparables

Screen With Investor

Name	Capital Allocation	Economic Moat	Market Cap
Eli Lilly and Co LLY	LOCK\|dr$S$>&	LOCK\|mC^	$1T
Johnson & Johnson JNJ	LOCK\|@M#!PZ	LOCK\|X%t	$619B
AbbVie Inc ABBV	LOCK\|NJc<Rr	LOCK\|bp	$438B
Roche Holding AG ADR RHHBY	LOCK\|!%G&Bnz!	LOCK\|gX	$333B
Novartis AG ADR NVS	LOCK\|MFdYx$&!	LOCK\|b>	$294B
AstraZeneca PLC AZN	LOCK\|&^&?Bmn>	LOCK\|Nj	$267B
Novo Nordisk AS ADR NVO	LOCK\|&@H?j@G<	LOCK\|zh	$218B
Amgen Inc AMGN	LOCK\|<Q<lSMD	LOCK\|F<	$196B
Gilead Sciences Inc GILD	LOCK\|!mQWZ?f	LOCK\|^W	$161B

Merck & Co Inc MRK

Company Report

Merck's Portfolio and Solid Late-Stage Pipeline Defend Against Upcoming Keytruda Headwinds

Price vs Fair Value

Bulls Say, Bears Say

Bulls

Bears

News

Merck, Pfizer, Astellas Bladder Cancer Treatment Approved by FDA

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)

Merck to Hold Second-Quarter 2026 Sales and Earnings Conference Call Aug. 4

Merck Announces New Agreement with ADAP Crisis Task Force to Improve Access and Care for People Living with HIV

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10) Advanced Triple-Negative Breast Cancer (TNBC)

European Commission Approves KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First PD-1 Inhibitor Plus Antibody-Drug Conjugate Regimen for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer

Merck's Tulisokibart Hits Key Goals in Phase 3 Ulcerative Colitis Study

Merck’s Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 ATLAS-UC Induction-only Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

Articles & Videos

As Biopharma Turns to China, ESG Risks and Geopolitics Remain in Focus

4 ‘Hold Forever’ Stocks That Have Stood the Test of Time

5 Long-Term Stocks to Buy Now and Hold for Decades

A Wave of Biotech IPOs May Be Starting—Here’s Why

The Best Companies to Own: 2026 Edition

Best Innovative Companies to Own: 2026 Edition

As Tech Struggles, Dividend Stocks Step Back Into the Limelight

Markets Brief: What’s Clipping Microsoft Stock, Pharma Earnings and Jobs Report on Deck

Why 2026 Could Be a Breakout Year for Dividend Stocks

Trading Information

Key Statistics

Company Profile

Competitors

Valuation

Financial Strength

Profitability

Drug Manufacturers - General Industry Comparables

Sponsor Center

What We Do

Company

Get Help